Drug Profile
RGH 618
Alternative Names: RGH-618Latest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Gedeon Richter
- Class
- Mechanism of Action Metabotropic glutamate receptor 5 agonists; Metabotropic glutamate receptor type 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 28 Apr 2018 No recent reports of development identified for phase-I development in Anxiety-disorders(In volunteers) in United Kingdom (PO, Capsule)
- 18 Apr 2016 Phase-I development is ongoing in United Kingdom